Abbott Laboratories

ABT

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000001800

C

middle fifth of 370 graded peers in healthcare

rank 205 of 370; percentile 55.3; sampling error 2.5 points; lower is stronger

A B C D E

C, the tortoise



Scoreboard	
Profitability	B/C percentile 41.5
Solvency	C percentile 54.9
Growth and financing	C percentile 52.4
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $86.7B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	11 of 14
Graded from	filings received through Feb 20, 2026 259 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026
Last close	$113.55 2026-11-05; market equity $196.7B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 20, 2026

Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market. The acquisition is subject to customary closing conditions, including the approval of Exact Sciences shareholders and obtaining the required regulatory clearances.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 41.5						
Gross profitability	28.8%	32.3%		52.2	365	2025-12-31
Return on invested capital	11.2%	9.3%		39.7	74	2025-12-31
Accruals ratio	(3.6%)	(6.6%)		68.4	802	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	0.7 pts	2.8 pts		5.8	242	2025-12-31
Solvency, sleeve percentile 54.9						
Twelve-month failure probability	not computable	0.07%				
liabilities and a nearby cover-page share count are required at 2026-09-30						
Altman Z double-prime	not computable	(0.37)				
one or more required annual facts are missing						
Net debt to EBITDA	0.46x	1.82x		31.1	75	2025-12-31
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	1.58x	2.94x		78.7	828	2025-12-31
Growth and financing, sleeve percentile 52.4						
Revenue growth, three-year compound	0.5%	10.0%		70.1	412	2025-12-31
Free cash flow growth, three-year compound	(1.8%)	10.9%		75.8	96	2025-12-31
Reinvestment rate	11.9%	37.1%		61.5	105	2025-12-31
Asset growth, three years	5.2%	2.2%		40.6	696	2025-12-31
Net share issuance, one year	0.2%	2.5%		14.0	630	2026-01-31

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
200	Cabaletta Bio, Inc. (CABA)	53.9	C	dilution
201	Zai Lab Ltd. (ZLAB)	54.2	C	
202	Emergent BioSolutions Inc. (EBS)	54.5	C	
203	Roivant Sciences Ltd. (ROIV)	54.7	C	fortress balance sheet
204	Teladoc Health, Inc. (TDOC)	55.0	C	fortress balance sheet
205	Abbott Laboratories (ABT)	55.3	C	
206	Neuronetics, Inc. (STIM)	55.6	C	
207	ELI Lilly & Co. (LLY)	55.8	C	
208	Inogen Inc. (INGN)	56.1	C	fortress balance sheet
209	AdaptHealth Corp. (AHCO)	56.4	C	
210	Aquestive Therapeutics, Inc. (AQST)	56.6	C	

What the price implies

at the 2026-11-05 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(18.6%)	(2.1%)	38
Distance from 52-week high	(13.0%)	(30.4%)	72
EBIT to enterprise value	3.9%	(1.5%)	72
Free cash flow yield	3.8%	(1.0%)	74
Book value to price	0.26	0.29	46
Sales to price	0.23	0.30	41
Composite equity issuance, five years	(12.7%)	21.4%	13

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Relative strength against the sector, log excess return	(0.37)	(0.19)	38

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$4.1B
Operating cash flow, four quarters	$8.9B
Months of runway	not finite
Days since last periodic filing	2 (10-Q received Nov 4, 2026)
Median daily dollar volume, 63 sessions	$847.3M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$44.3B	2025-12-31	2026-02-20	10-K	26-010185
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$19.3B	2025-12-31	2026-02-20	10-K	26-010185
3	assets	us-gaap:Assets	$86.7B	2025-12-31	2026-02-20	10-K	26-010185
4	operating income	us-gaap:OperatingIncomeLoss	$8.1B	2025-12-31	2026-02-20	10-K	26-010185
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$8.5B	2025-12-31	2026-02-20	10-K	26-010185
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$1.9B	2025-12-31	2026-02-20	10-K	26-010185
7	total debt	us-gaap:LongTermDebt	$12.9B	2025-12-31	2026-02-20	10-K	26-010185
8	book equity	us-gaap:StockholdersEquity	$52.1B	2025-12-31	2026-02-20	10-K	26-010185
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$8.5B	2025-12-31	2026-02-20	10-K	26-010185
10	total debt	us-gaap:LongTermDebt	$14.1B	2024-12-31	2026-02-20	10-K	26-010185
11	book equity	us-gaap:StockholdersEquity	$47.7B	2024-12-31	2026-02-20	10-K	26-010185
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$7.6B	2024-12-31	2026-02-20	10-K	26-010185
13	net income	us-gaap:NetIncomeLoss	$6.5B	2025-12-31	2026-02-20	10-K	26-010185
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$9.6B	2025-12-31	2026-02-20	10-K	26-010185
15	assets	us-gaap:Assets	$81.4B	2024-12-31	2026-02-20	10-K	26-010185
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$42.0B	2024-12-31	2026-02-20	10-K	26-010185
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$18.7B	2024-12-31	2026-02-20	10-K	26-010185
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$40.1B	2023-12-31	2026-02-20	10-K	26-010185
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$18.0B	2023-12-31	2026-02-20	10-K	26-010185
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$43.7B	2022-12-31	2025-02-21	10-K	25-007110
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$19.1B	2022-12-31	2025-02-21	10-K	25-007110
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$43.1B	2021-12-31	2024-02-16	10-K	24-005348
23	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$18.5B	2021-12-31	2024-02-16	10-K	24-005348
24	depreciation amortization	us-gaap:Depreciation	$1.4B	2025-12-31	2026-02-20	10-K	26-010185
25	operating income	us-gaap:OperatingIncomeLoss	$6.5B	2023-12-31	2026-02-20	10-K	26-010185
26	interest expense	us-gaap:InterestExpense	$637.0M	2023-12-31	2024-02-16	10-K	24-005348
27	current assets	us-gaap:AssetsCurrent	$26.0B	2025-12-31	2026-02-20	10-K	26-010185
28	current liabilities	us-gaap:LiabilitiesCurrent	$16.5B	2025-12-31	2026-02-20	10-K	26-010185
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.2B	2025-12-31	2026-02-20	10-K	26-010185
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$8.6B	2024-12-31	2026-02-20	10-K	26-010185

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.2B	2024-12-31	2026-02-20	10-K	26-010185
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$7.3B	2023-12-31	2026-02-20	10-K	26-010185
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.2B	2023-12-31	2026-02-20	10-K	26-010185
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$9.6B	2022-12-31	2025-02-21	10-K	25-007110
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.8B	2022-12-31	2025-02-21	10-K	25-007110
36	current assets	us-gaap:AssetsCurrent	$23.7B	2024-12-31	2026-02-20	10-K	26-010185
37	current liabilities	us-gaap:LiabilitiesCurrent	$14.2B	2024-12-31	2026-02-20	10-K	26-010185
38	assets	us-gaap:Assets	$73.2B	2023-12-31	2025-02-21	10-K	25-007110
39	assets	us-gaap:Assets	$74.4B	2022-12-31	2024-02-16	10-K	24-005348
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,737,682,887	2026-01-31	2026-02-20	10-K	26-010185
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,734,323,411	2025-01-31	2025-02-21	10-K	25-007110

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.